All In Biotech

Drug Trial Radar · NCT02232308

Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jul 2014

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Adil BharuchaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Center for Research Resources (NCRR); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Sep 5, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy subjects.

Conditions

  • Gastroparesis

Interventions

  • NizatidineDrug

    Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

  • LisinoprilDrug

    Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

  • PlaceboDrug

    Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in plasma heme oxygenase 1 (HO-1) protein concentrationTime frame: Day 3, Day 10
  2. Change in Monocyte HO-1 activityTime frame: Day 3, Day 10

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Rochester

    Rochester, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.